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Introduction Methods Results
Conclusions
Cortical injuries, such as those caused by stroke are 
a major cause of long-term disability1. Currently there 
are no pharmacological therapies on the market that 
are able to treat chronic sequelae from stroke. This 
chronic damage can leave individuals with paraplegia 
that persists indefinitely after the initial injury. 
Recently, various types of stem cells have arisen as a 
potential treatment for chronic damage following 
stroke in human patients. 
SanBio Inc. recently completed a Phase 1/2a clinical 
trial with intracranial implantation of modified bone 
marrow-derived mesenchymal stem cells, SB623, 
which appear to be safe and were associated with 
improvements in clinical outcome in some patients for 
24 months post implantation. However, the 
mechanisms by which these cells reduce neurological 
deficits remain unknown. Past research indicates 
that cortical stroke can lead to hyperexcitability in 
surrounding circuits and increased inflammation. 
Therefore in this preclinical study, we study whether 
SB623 can ameliorate circuit deficits through slice 
electrophysiology, and decrease inflammation by 
staining for GFAP and Iba1.
LFP Slice Recordings
Photothrombotic Stroke Model
Fig. 1 IP Injection of 
Rose Bengal Solution 
(40 mg sol/kg rat), which 
is a light sensitive dye 
that creates free radicals 
in the artery after 
exposure to light, which 
in turn induce stroke. 
Placed Light source 
(562 nm) on S1 cortex 
at the coordinates (AP -
2.5 , ML +5.0). 
Fig. 2 Implanted SB623 or vehicle 
into periinfarct region of the S1 
Cortex 28 days after induction of 
stroke. Three injection sites, 
located at (AP -1, ML +4, DV 1.8), 
(AP -2.5, ML +3.5, DV 1.4), (AP -4, 
ML +5, DV 1.3), were used.  The 
same implantation protocol was 
used for the electrophysiology, 
cell survival and 
immunohistochemistry studies.
Results
Fig. 4 Square box is highlighting the stroke area and the presence of 
SB623. Green fluorescent specks are the presence of the injected 
SB623 by staining for Stem 121, a human cell marker.  After staining, 
the slices were imaged and cells were counted using image J.  
Percentage cell survival was then calculated.
Methods
SB623 & Vehicle Implantation
Fig. 3 . Using slice multi-array electrophysiology we measured 
the changes in the cortical circuitry by recording the local field 
potential (LFP) across the different cortical layers and assessing 
the current source density. 16-Channel Neuronexus probes were 
placed in the cortical column, 1 mm from the stroke region, and 
stimulated by a probe placed directly below in the white tract. 
Stroke area is under the green recording probe, indicated by the 
black arrow.  14 days after implantation of SB623 or vehicle 
(plasmalyte), animals were sacrificed and their brains were sliced 
on a Leica vibrotome in 400um sections.  Animal tissue was kept 
alive and suspended in oxygenated artificial cerebrospinal fluid 
(ACSF) for the duration of the recordings.
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Results
1. Cell survival
2. Cells dampen the cortical network 
hyperexcitability after stroke
3. Cells dampen the inflammation in the peri-
stroke cortex
Fig. 5 . The following graphs show the input 
output curves for amplitude across 10 different 
intensities. There is a significant difference 
between the stroke+vehicle phenotype and all 
other groups in layers 1-3 and in layer 4.  Layer 
5-6 show no significant differences.  Statistics 
comparing stroke vehicle to all other groups 
exhibited a p-value <.001.  Comparing all other 
groups yield a p-value > .50. 
Iba1
Sham Vehicle Stroke CellsStroke Vehicle
Fig. 7 . Above shows fluorescence images of the GFAP and Iba1 
stains in the cortex lateral to stroke region. At right is quantification 
of the above images, comparing ipsilateral to contralateral 
fluorescence.  Quantification suggests that SB623 ameliorates 
inflammation in the peri-stroke region.
From the results obtained in the previous studies we can conclude 
the following:
• After injection of SB623 in the peri-stroke region, cells persist 
through 72 hours but are completely gone by the 7 day time 
point.
• Electrophysiological results confirm that stroke injury leads to 
hyperexcitablity in the peri-stroke region as seen in amplitude 
(shown left) and line length (not shown) in the superficial layers.
• Electrophysiological results also show that treatment with SB623 
dampens the cortical network hyperexcitability back to normal 
levels.
• Immunohistochemistry results suggest that cortical 
hyperexcitabiltiy results from increased inflammatory activity in 
the peri-stroke region, which is subsequently dampened by 
introduction of SB623 back to close to normal levels.
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Fig. 6 . Below are CSDs and traces for each of the groups.  The Y-axis 
shows responses from the 16 channels (1-16 up).  The X-axis shows 
the time interval of 20 seconds post stimulation. Stroke Vehicle group 
exhibits increased response after stimulation.
GFAP
1Emelia J. Benjamin et al. “Heart Disease and Stroke Statistics 2017: A Report From 
the American Heart Association.” AHA Journal. Volume 136, Issue 17. 2017.
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